Mineralys Therapeutics to Participate in the Guggenheim Securities 6th Annual Biotechnology Conference

Rhea-AI Summary

Mineralys Therapeutics, Inc. CEO Jon Congleton will participate in a fireside chat at the Guggenheim Securities 6th Annual Biotechnology Conference in New York City on February 8, 2024. The company focuses on developing medicines for hypertension, chronic kidney disease, and other diseases driven by elevated aldosterone levels.

RADNOR, Pa., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone, today announced that Chief Executive Officer Jon Congleton will be participating in a fireside chat at the Guggenheim Securities 6^th Annual Biotechnology Conference, being held in New York City on February 7-8, 2024.

Guggenheim Securities 6th Annual Biotechnology Conference:
Date:	Thursday, February 8, 2024
Time:	9:00am EST
Format:	Fireside Chat

A live webcast of the fireside chat can be accessed under “News and Events” on the Investor Relations section of the Mineralys website at www.mineralystx.com. A replay of the fireside chat will be available on the Company’s website for approximately 90 days.

About Mineralys Therapeutics
Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, CKD and other diseases driven by abnormally elevated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that Mineralys Therapeutics is developing for cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and CKD. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn and Twitter.

Contact:

Investor Relations
investorrelations@mineralystx.com

Media Relations
Tom Weible
Elixir Health Public Relations
Phone: (1) 515-707-9678
Email: tweible@elixirhealthpr.com

FAQ

When and where will the Guggenheim Securities 6th Annual Biotechnology Conference take place?

The conference will be held in New York City on February 7-8, 2024.

What is the focus of Mineralys Therapeutics, Inc.?

The company is focused on developing medicines for hypertension, chronic kidney disease, and other diseases driven by abnormally elevated aldosterone.

Where can the live webcast of the fireside chat be accessed?

The webcast can be accessed under 'News and Events' on the Investor Relations section of the Mineralys website at www.mineralystx.com.

How long will the replay of the fireside chat be available on the company's website?

The replay will be available for approximately 90 days on the company's website.